Objectives: This study investigates whether administration of low doses of gadoliniumbased contrast agent (GBCA) for dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) can be as effective as a standard dose in distinguishing prostate cancer (PCa) from benign tissue. In addition, we evaluated the combination of kinetic parameters from the low-and high-dose injection as a new diagnostic marker. Materials and Methods: Patients (n = 17) with histologically confirmed PCa underwent preoperative 3 T MRI. Dynamic contrast-enhanced MRI images were acquired at 8.3-second temporal resolution with a low dose (0.015 mmol/kg) and close to the standard dose (0.085 mmol/kg) of gadobentate dimeglumine bolus injections. Low-dose images were acquired for 3.5 minutes, followed by a 5-minute gap before acquiring standard dose images for 8.3 minutes. The data were analyzed qualitatively to investigate whether lesions could be detected based on early focal enhancement and quantitatively by fitting signal intensity as a function of time with an empirical mathematical model to obtain a maximum enhancement projection (MEP) and signal enhancement rate (α). Results: Both low-and standard-dose DCE-MRI showed similar sensitivity (13/ 26 = 50%) and lesion conspicuity score (4.0 ± 1.0 vs 4.2 ± 0.9; P = 0.317) for PCa diagnosis on qualitative analysis. Prostate cancer showed significantly increased α compared with benign tissue for low (9.98 ± 5.84 vs 5.12 ± 2.95 s ) dose. The ratio of low-dose α to standard-dose α was significantly greater (P = 0.02) for PCa (2.8 ± 2.3) than for normal prostate (1.6 ± 0.9), suggesting changes in water exchange and T2* effects associated with cancer. In addition, decreases in the percentage change in T1 relaxation rate as a function of increasing contrast media concentration (ie, the "saturation effect") can also contribute to the observed differences in high-dose and low-dose α. Area under the receiver operating characteristic curve for differentiating PCa from benign tissue using α was higher for low dose (0.769) compared with standard dose (0.625). There were no significant differences between MEP calculated for PCa and normal tissue at the low and standard doses. Moderate significant Pearson correlation for DCE parameters, MEP (r = 0.53) and α (r = 0.58), was found between low and standard doses of GBCA. Conclusions: These preliminary results suggest that DCE-MRI with a low GBCA dose distinguishes PCa from benign prostate tissue more effectively than does the standard GBCA dose, based on signal enhancement rate. Diagnostic accuracy is similar on qualitative assessment. Prostate cancer diagnosis may be feasible with DCE-MRI with low-dose GBCA. In addition, comparison of enhancement kinetics after low and high doses of contrast media may provide diagnostically useful information.
D
ynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is used to diagnose various clinical conditions, especially cancers of the breast, prostate, pancreas, cervix, lungs, and the brain. [1] [2] [3] [4] [5] [6] Dynamic contrast-enhanced MRI is performed by acquiring serial T1-weighted (T1W) images before and after the bolus injection of a low-molecularweight contrast media, which is generally a chelated gadolinium (Gd) molecule. Despite the effectiveness of DCE-MRI in detecting various pathologies, there are risks associated with Gd injection. Nephrogenic systemic fibrosis, edema, and erythema are associated with the use of Gd-based contrast agents (GBCAs). 7 Although 1 study found no significant Gd deposition after the administration of Gd-based contrast agents, 8 several studies found evidence of Gd deposition in the body (brain, bone, kidneys, etc) after MRI scans, [9] [10] [11] [12] and another study showed that unchelated Gd 3+ is released into blood after injection. 13 The contrast agents are chelated Gd ion, which is not toxic. However, Gd in the free ionic form (Gd 3+ ) is highly toxic in humans. 14, 15 In light of these results, the Pharmacovigilance and Risk Assessment Committee for the European Medicines Agency has recommended the suspension of certain contrast agents that may result in higher Gd deposition.
Although the deposition of Gd has been demonstrated in numerous studies, the clinical consequences of Gd deposition are unknown. 9 At the same time Gd-enhanced MRI scans provide crucial medical information. Therefore, the American College of Radiology recommends that clinical diagnostic benefits should be considered against the unknown potential risk of Gd deposition.
Multiparametric MRI (mpMRI) is recommended for the diagnosis of prostate disease. 16, 17 Importantly, DCE-MRI is an integral part of the mpMRI technique, with cancers showing early focal signal enhancement because of angiogenesis. 16, 18 Because patients often undergo multiple MRIs, it is reasonable to test the feasibility of DCE-MRI using a decreased Gd dose for prostate cancer (PCa) diagnosis to reduce the risks associated with Gd deposition.
In addition to reducing the risk of adverse reactions, low doses of contrast media may have other advantages. Lower doses reduce potentially confounding effects of water exchange 19, 20 and T2* effects [21] [22] [23] associated with standard doses and may allow more accurate measurements of contrast media concentration. In addition, contrast media dose-dependent effects may be different for cancers compared with normal tissue, for example, because of differences in water exchange across cell membranes or blood vessel density and leakiness producing differing T2* effects. Therefore, comparison of enhancement kinetics after low versus high doses of contrast media may provide diagnostically useful information. This feasibility study investigated whether administration of low doses of GBCA for DCE-MRI can be as effective as a standard dose in distinguishing PCa from benign tissue. In addition, we investigated whether the combination of a low dose followed by a high dose of contrast media is advantageous.
MATERIALS AND METHODS
This prospective study was conducted after institutional review board approval and informed patient consent were received and was compliant with the Health Insurance Portability and Accountability Act. Seventeen consecutive patients were recruited in this study, with previous biopsy-proven PCa scheduled to undergo radical prostatectomy. No patients with previous radiation or hormonal therapy were scanned. The patients were imaged between February 2014 and August 2014.
Magnetic Resonance Imaging
The MRI was performed on Philips Achieva 3 T TX scanner (Philips Healthcare, Best, the Netherlands) using a 6-channel cardiac phased array coil placed around the pelvis combined with an endorectal coil (Medrad, Bayer Healthcare). Barium sulfate suspension was used to inflate the endorectal coil to squeeze air out to effectively reduce susceptibility and motion artifacts. 24 The mpMRI protocol included T2W imaging, diffusion-weighted imaging, and T1W DCE-MRI. Two sets of axial dual-echo 3-dimensional (3D) T1W DCE-MRI data were acquired at a temporal resolution of 8. ; SENSitivity Encoding factor,1.67; and partial Fourier factor,0.675. A 2-point modified Dixon (mDixon) method was used to produce the "water-only" images for quantitative analysis. 25, 26 The total amount of gadobenate dimeglumine (Multihance, Bracco, Minneapolis, MN) injected was based on the patient's weight (0.1 mmol/kg). The dose was divided into 2 components: first, a low dose of contrast agent, 0.015 mmol/kg (15% of total), and second, a dose of 0.085 mmol/kg (85% of the standard dose, but referred to here as the "standard" dose). The injection rate was 0.35 and 2.00 cc/s for low and standard GBCA dose, respectively, so that the total injection times were the same for the 2 doses. Images were acquired for 3.5 minutes after the low dose, because we were primarily interested in the early uptake kinetics after the low dose. This was followed by a 5-minute gap before acquiring images after a standard dose of contrast media for 8.3 minutes.
Histology-MRI Match
All study subjects subsequently underwent radical prostatectomy, and whole mount specimen processing of excised prostates was performed by the pathology department at our institution. The whole prostate was fixed in formalin and sectioned in approximately the same plane as magnetic resonance (MR) images using the standard approach. Whole mount sections were hematoxylin-eosin stained and mounted on glass slides. Cancer outlines were marked by an expert pathologist (TA, 10 years of experience) on hematoxylin-eosin-stained histology images. The specimens were compared with the preoperative MRI in a retrospective fashion, and the cancerous lesions marked on histological slides were identified on MRI. The MR images acquired with different pulse sequences and histology images were coregistered to T2W images using rigid registration in 3D Slicer. 27 The MR images were analyzed by an expert radiologist (AO, 15 years of prostate MRI experience). Regions of interest (ROIs) were drawn on axial T2W images and transferred to DCE images using "PCampReview," a custom-made module for prostate mpMRI in 3D Slicer (https://github.com/rcc-uchicago/ PCampReview). Pathology confirmed cancers on prostatectomy specimens less than 5 mm in dimension were not included in the analysis.
Qualitative DCE-MRI Analysis
The low-and standard-dose DCE-MRI images were analyzed retrospectively by an expert radiologist (AO, 15 years of prostate MRI experience). The PCa lesions were verified to see whether they showed early focal enhancement post contrast injection, which was indicative of PCa presence. Prostate cancer lesions detected based on early focal enhancement were assigned a lesion conspicuity score of 1 to 5 based on the confidence in accurately detecting cancer, with 5 being the highest confidence in accurately differentiating PCa from benign tissue on early-phase DCE-MRI images.
Quantitative DCE-MRI Analysis
The MR data were analyzed using in-house software written in MATLAB (Mathworks, Natick, MA) to generate DCE parameter maps. The DCE-MRI analysis was performed using the empirical mathematical model (EMM) described in Fan et al. 28 The baseline signal intensity value (S 0 ) of each voxel was calculated by averaging the signal intensity (S(t)) of the 5 precontrast time points. Then, the percentage signal enhancement (PSE) as a function of time was calculated as
The initial time of enhancement for each voxel was found using an iterative method described in a previous study. 29 The maximum enhancement projections (MEPs) were generated by finding the maximum PSE value of each voxel. The PSE curve of standard dose data was fitted with the EMM on a voxel-by-voxel basis with a nonlinear leastsquares algorithm using the following equation:
where A is the amplitude of PSE, α is the uptake rate (s
), and β is the washout rate (s
−1
). As the duration of acquisition after the low dose of contrast media was relatively short (3.5 minutes), no washout phase was detected. Thus, the low-dose PSE curve versus time data were fitted to a truncated (uptake only) EMM using the following equation:
where A is the amplitude of PSE, and α is the uptake rate (s
). There were concerns that contrast retention from the low-dose injection could interfere with the analysis of the contrast media kinetics after the standard dose injection (~8.5 minutes after the low-dose injection). Therefore, we calculated the percentage difference between baseline signal intensity before the low dose (LD baseline ) and signal intensity immediately before the standard dose (SD baseline ) using the following equation:
Statistical Analysis
Statistical analysis was performed using SPSS (IBM Corporation, Armonk, NY). The difference in lesion conspicuity score assigned by the radiologist for low-and standard-dose images was assessed by Wilcoxon signed rank test. Means and standard deviations for DCE-MRI parameters from the EMM (α, β, and MEP) were calculated for all the annotated ROIs for both low-dose and standard-dose DCE-MRI scans. The differences in means of the DCE parameters for cancer and normal prostatic tissue were assessed by 2-tailed independent sample t test. Receiver operating characteristic (ROC) analysis was used to evaluate the performance of the quantitative DCE-MRI parameters in differentiating between PCa and normal tissue. The Pearson correlation coefficient between DCE-MRI parameters from the low-dose and standard-dose scans was estimated.
RESULTS
The mean age of the 17 patients recruited in this study was 55 years (range, 43-70 years), and mean prostate specific antigen (PSA) level before MRI was 7.8 ng/mL (range, 1.8-25.0 ng/mL). Twenty-six ROIs from cancer (6 Gleason score 3 + 3, 17 Gleason score 3 + 4, and 3 Gleason score 4 + 3) (21 peripheral zone cancers, 4 transition zone cancers, and 1 anterior fibromuscular cancer) and 35 ROIs from normal tissue (11 from peripheral zone, 8 from transition zone, 8 from central zone, and 8 from anterior fibromuscular stroma) were analyzed in this study. Mean tumor size at its largest extent in the axial plane was 2.1 ± 1.4 Â 1.0 ± 0.5 cm 2 (range, 0.5-6.9 Â 0.3-2.2 cm 2 ). The qualitative assessment of DCE-MRI images by an expert radiologist showed similar sensitivity for PCa detection using both-low and standard-dose DCE-MRI. Of 26 PCa lesions, 13 (sensitivity = 13/ 26 = 50%) showed early focal enhancement on low-dose and highdose DCE-MRI, which was considered as indicative of PCa presence. The lesion conspicuity score for lesion detected was only nominally higher (Z = −1.000, P = 0.317) on standard clinical dose images (4.2 ± 0.9) compared with low-dose images (4.0 ± 1.0). Figures 1 and 2 show the voxel-by-voxel representations of quantitative DCE-MRI parameters (enhancement rate or α) and early phase DCE-MRI images from both low and standard GBCA doses, along with the final pathological outcome in corresponding T2W images and histology images with cancer outlined. Prostate cancer is seen as regions of increased signal enhancement rate compared with surrounding benign tissue. The values of DCE-MRI parameters from the EMM analysis for low-and standard-dose Gd administration and the statistical results are shown in Table 1 .
Signal Enhancement Rate (α)
; P < 0.001), ; P = 0.06). The rate constants for both PCa and benign tissue are larger for the low dose than the standard dose. Figure 3 summarizes α values from cancer and normal tissue ROIs for standard-and low-dose DCE-MRI. In addition, the ratio of low-dose α to standard-dose α was significantly greater (P = 0.02) for PCa (2.8 ± 2.3) than for normal prostate (1.6 ± 0.9), suggesting changes in water exchange and/or T2* effects associated with cancer. The area under the ROC curve (AUC) for differentiating PCa from benign tissue using α was nominally (P = 0.14) higher for low dose (0.769, P < 0.001) compared with standard dose (0.625; P = 0.10).
Maximum Enhancement Projection
There were no significant differences between MEP calculated for PCa and normal tissue at both low dose (33.3% ± 11.6% vs 28.9% ± 16.3%; p = 0.24) and standard dose (110.2% ± 49.4% vs 93.8% ± 42.5%; P = 0.17). The ROC analysis results in Table 1 also show that MEP values were not effective in differentiating between cancer and benign tissue evidenced by nonsignificant low AUC values.
Washout Rate (β)
This imaging protocol study only followed the washout phase for the standard dose administration. There was no significant difference (P = 0.24) for the washout rate (β) between cancer (0.146 ± 0.545 %/s) and normal tissue (0.032 ± 0.151 %/s).
Correlation Between Low-and Standard-Dose DCE-MRI Parameters
A modest but statistically significant Pearson correlation for DCE-MRI parameters (MEP, r = 0.53, P < 0.05; and α, r = 0.58, P < 0.05) was found between low and standard doses of Gd. Figure 4 shows the correlation of the DCE-MRI parameters between low-and standard-dose DCE-MRI.
Contrast Retention From Low Dose
The overall difference in baseline signal intensity between the low-and standard-dose DCE-MRI protocols due to retention of contrast from the low-dose injection is 8.9% ± 14.1%. In addition, there is no significant difference (P = 0.08) between contrast media retention in PCa (12.7% ± 11.4%) and normal prostate (6.9% ± 14.9%).
DISCUSSION
Although DCE-MRI is an important method for detecting PCa, there are concerns with the potential for adverse reactions and deposition in the body, specifically in the brain and liver. The clinical benefit from DCE-MRI outweighs the unknown potential risk of Gd deposition, but the balance between risk and benefit would improve if the risk could be reduced. Therefore, this study investigated whether administration of low doses of Gd for DCE-MRI can be as effective as a standard dose in distinguishing PCa from benign tissue. The results show that PCa diagnosis is feasible with quantitative DCE-MRI with a low dose of Gd-based contrast agent. Surprisingly, a very small contrast agent dose-15% of the standard clinical dose-provides some advantages in diagnostic performance. This is likely because of the fact that T2* and water exchange effects are much smaller when a lower dose of contrast is used. These effects are large at higher doses and can obscure differences between cancer and normal prostate. In addition, the subsequent percentage enhancement produced by additional contrast agent decreases as the tissue concentration of contrast media increases further (and T1 decreases). Thus, larger doses of contrast agent are increasingly inefficient in producing enhancement and improved image contrast; that is, there is a "saturation effect" at high contrast media concentrations. Smaller doses of contrast agent may produce improved diagnostic benefit per millimole of contrast media.
Both low-and standard-dose DCE-MRI showed similar sensitivity and lesion conspicuity score for PCa diagnosis on qualitative analysis by an expert radiologist based on early enhancement post injection. Signal enhancement rate (α) is effective in differentiating the PCa and normal tissue. Quantitative DCE-MRI with a low Gd dose better distinguishes PCa from benign prostate tissue than does one with a standard Gd dose, based on signal enhancement rate, as evidenced by the higher AUC for PCa differentiation using low-dose DCE-MRI compared with standard dose. The AUC value for PCa diagnosis with high-dose DCE-MRI is similar to those found in other DCE-MRI studies, whereas the AUC value obtained with low-dose DCE-MRI is similar to the highest value reported from previous studies. [30] [31] [32] Although no previous studies have attempted low-dose DCE-MRI in the diagnosis of PCa, the results of our study showing that low-dose GBCA is as effective as standard-dose GBCA for PCa diagnosis are consistent with a study by Huang et al 33 that showed that comparable contrast enhancement of brain metastases can be achieved with a low dose (50% of standard clinical dose) of gadobenate dimeglumine at 3 T compared with imaging at 1.5 T using standard-dose gadopentetate dimeglumine. An older study on the central nervous system by Haustein et al 34 showed that a higher dose (3 times standard dose) of GBCA provided better contrast and efficacy, but this may be the result of the lower field strength (0.5 T) used for this study.
The correlation between DCE-MRI parameters for low and standard doses of Gd was statistically significant but relatively weak. The low-dose α and high-dose α are well correlated for benign ROIs but poorly correlated for cancer ROIs. This suggests that the low dose of contrast media is providing new information that may compliment, rather than duplicate, the information from the standard clinical dose. The weak correlation between quantitative DCE-MRI parameters for low and standard dose may be because of the sensitivity to T2* and water exchange effects, [21] [22] [23] as well as the native T1, and therefore, these differences may be diagnostically useful. This study in fact, found the ratio of low-dose α to standard-dose α to be significantly greater for PCa than for normal prostate, which suggests that there should not be a strong correlation between low-dose and high-dose parameters.
The current results suggest that a lower dose of contrast may provide at least the same diagnostic accuracy as a full dose, based on semiquantitative analysis of data. But in addition, the results suggest that a protocol that combines a low dose followed by a high dose may provide novel and diagnostically useful information. The ratio of low-dose α to standard-dose α was significantly greater for PCa than for normal prostate. This difference may reflect water exchange and T2* effects that may be markers for cancer. [21] [22] [23] In addition, as demonstrated by previous work from this laboratory, 26 analysis of the arterial enhancement after the low dose provides an accurate arterial input function, and this arterial input function can then be used for quantitative analysis of contrast media dynamics in the cancer. Thus, a protocol composed of a low-contrast media dose followed, after a washout period, by a high-contrast media dose may provide more benefits for patients than would a conventional protocol that delivers the entire dose in a single bolus. The MEP is not significantly different between cancer and benign tissue and therefore is not helpful for PCa detection for both the low-and standard-dose DCE-MRI. These results are similar to those of the previous study showing that even though the contrast media bolus arrival time and MEP are similar for benign prostatic tissue and PCa, the faster rate of initial enhancement in PCa compared with benign tissue observed in this study, characterized by signal enhancement rate (α), may appear similar to early enhancement in PCa. 29 In addition, the signal washout rate for standard dose DCE-MRI is shown to be ineffective for PCa detection, similar to the results reported in the previous paper from this group.
The choice of Gd-based contrast agent should be considered for low-dose DCE-MRI studies. The contrast agent used in this study, gadobenate dimeglumine, has the highest relaxivity among the clinically approved contrast agents, which makes it the ideal contrast agent for this study investigating the feasibility of low-dose DCE-MRI. The high relaxivity comes from weak interactions with albumin and some other macromolecules-mostly in blood. Because of this weak binding, during the first pass of the bolus, the contrast agent remains longer in the blood. The prolonged higher concentrations of contrast media in blood mean larger T2* and water-exchange effects in and near blood vessels. This could have accentuated differences between the low dose and high dose. The DIXON sequence produces additional T2* effects, although other fat suppression methods also produce T2* effects owing to spectrally selective pulses. Therefore, it would be interesting to compare low and standard clinical doses with other contrast agents and pulse sequences.
In addition to the imaging pulse sequence, other imaging parameters used for both low-and standard-dose DCE-MRI protocol were also kept consistent with standard clinical prostate MRI. The flip angle used in this study was the same as the flip angle used for standard clinical exams. A larger pulse angle may have yielded better contrast for the low dose because the low dose produces smaller T1 changes. In addition, the use of high-temporal-resolution DCE-MRI may improve the diagnostic performance, as shown in a previous study, 29 particularly in combination with a rapid bolus injection of a low-dose GBCA. This preliminary study did not explore optimal parameter settings for the low-dose injection, but this is an important goal for future work.
There are a few limitations of this study:
1. The Toft model 35 was not used for the analysis presented here to avoid error propagation associated with measurement of the arterial input function and calculation of contrast media concentration in the lesion. However, use of compartmental models to analyze lowdose data will be investigated in the future. 2. The washout rate (β) for the low-dose DCE-MRI could not be accurately measured because the washout phase was sampled for a relatively short period of time. 3. The analysis of residual enhancement at~8.5 minutes after the low dose suggests that a small amount of contrast media from the lowdose injection remained when the standard-dose injection was injected, and this could interfere with the analysis of the uptake and washout kinetics after the standard dose. Despite the small amount of contrast retention, the residual contrast from the low dose may have reduced the dynamic range of enhancement after the standard dose. To reduce these limitations, a longer sampling period after the injection of the low dose would be beneficial. However, this would increase scan times, which might not be feasible in clinical practice.
4. This study investigated only 1 low dose of contrast media and 1 injection speed. Further work is needed to determine the dose and injection speed that is optimal for PCa diagnosis and reduces the risk of adverse events. 5. The differences observed between low and high doses may have been due in part to use of the DIXON technique to separate fat and water signals. This method uses 2 gradient echoes and thus is susceptible to T2* effects, especially during the first pass of the contrast media bolus. Other commonly used fat suppression methods based on spectrally selective inversion or saturation are also sensitive to changes in T2*. A systematic evaluation of T2* effects and a comparison of low-dose DCE-MRI with different fat suppression protocols are needed. 6. This preliminary study did not investigate whether low-dose DCE has any on effect on the clinical interpretation or PI-RADS scoring because of the small sample size in this study. This is an important topic that future studies will investigate.
In conclusion, PCa diagnosis may be feasible with DCE-MRI using a low-dose GBCA. Qualitative assessment yielded similar sensitivity and lesion conspicuity score for PCa diagnosis on qualitative analysis of both low-and standard-GBCA-dose DCE-MRI. However, quantitative analysis of enhancement kinetics distinguished PCa from benign prostate tissue more effectively with the low dose compared with the standard GBCA dose, based on signal enhancement rate in this preliminary study. The potential improvement with low dose may be the result of water exchange and T2* effects, as well as "saturation effects" at higher contrast media concentrations. In addition, comparison of contrast media kinetics after the low and high doses may provide useful information. Further study is needed to find the optimal dose and injection protocol for PCa diagnosis using DCE-MRI.
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